Spelling suggestions: "subject:"reninangiotensin"" "subject:"reninaangiotensina""
111 |
Bloqueadores farmacológicos do sistema renina-angiotensina e a regulação do metabolismo de adipócitos isolados. / Pharmacological blockers of the renin-angiotensin system and the regulation of the metabolism in isolated fat cells.Rennan de Oliveira Caminhotto 21 May 2014 (has links)
Dados recentes apontam para a participação do sistema renina-angiotensina (SRA) em processos metabólicos, devido a sua presença local em tecidos metabolicamente ativos, como o tecido adiposo, e sugerem que tais tecidos também poderiam ser alvos dos bloqueadores do SRA. Por isso, investigamos possíveis efeitos diretos de bloqueadores do SRA no metabolismo celular de adipócitos isolados. Para isso, adipócitos isolados foram tratados com doses não tóxicas de Alisquireno ou Captopril ou Losartan. Após 24 horas, as capacidades lipolíticas, lipogênicas e oxidativas foram. Como resultados, o fármaco Alisquireno, aumentou a relação entre oxidação de glicose e incorporação desse substrato em lipídeos, enquanto o Captopril diminuiu a incorporação de glicose em lipídeos, particularmente na fração glicerol do TAG mediante estímulo com insulina, bem como diminuiu a expressão gênica de receptor de (pró) renina. Como conclusão, os fármacos Captopril e Alisquireno podem modular o metabolismo lipogênico e oxidativo de adipócitos isolados, mas de maneiras diferentes. / Recent data indicate a participation of the renina-angiotensin system (RAS) in metabolic process, due its local presence in tissues, like the adipose tissue, and suggests that these tissues could be targets of RAS blockers. Therefore, we have studied the possible effects of pharmacological RAS blockers in isolated fat cells. Therefore, fat cells were isolated of epididymal fat pad and treated with non toxic doses of Aliskiren or Captopril or Losartan. After 24 hours, the lipolytic, lipogenic and oxidative capacity were tested in their respective spontaneous and stimulated states. Also, gene expression of PPARg and RAS components were verified. The results showed Aliskiren increases the relation between oxidation and lipogenesis from glucose, whereas Captopril decreased glucose lipid incorporation, especially in glicerol fraction of triglyceride when insulin stimulus exist, and the Renin receptor gene expression. As a conclusion, Captopril and Aliskiren can directly modulate lipogenic and oxidative metabolism of isolated fat cells, but in a different way.
|
112 |
O tratamento com leptina por 7 e 28 dias altera a função e a morfologia renal de ratos. / Leptin treatment for 7 and 28 days changes renal function and morphology in rats.Karina Thieme 15 July 2014 (has links)
O objetivo deste estudo foi avaliar os efeitos morfofuncionais da leptina por 7 e 28 dias sobre os rins e a participação do Sistema Renina-Angiotensina (SRA) neste processo. Os animais tratados por 7 dias apresentaram redução no ganho de peso (p<0.05), aumento da pressão arterial (PA, p<0.05), sem alterar o fluxo plasmático renal (FPR) e o ritmo de filtração glomerular (RFG). Também apresentaram aumento na fração de filtração (FF) (p<0.05), diurese e natriurese. No tratamento por 28 dias houve aumento da PA (p<0.05), queda no FPR (p<0.05), nenhuma alteração no RFG e aumento na FF (p<0.05). Ambos os grupos apresentaram hipertrofia glomerular, aumento da expressão de desmina e proteinúria. Os estudos in vitro demonstraram que a leptina (100 e 250 ng/ml, por 72 horas) induziu apoptose de células mesangiais. Em conclusão, o tratamento com leptina por 7 e 28 dias levou a alterações morfofuncionais renais e estas são, em grande parte, normalizadas com o Losartan, evidenciando uma interação entre a leptina e o SRA sistêmico, neste modelo experimental. / The aim of this study was to evaluate the morphofunctional effects of leptin treatment for 7 and 28 days on kidneys and the participation of the Renin-Angiotensin System (RAS) in this process. The animals treated for 7 days showed a reduction in weight gain (p<0.05), enhancement of blood pressure (BP; p<0.05), without changes in renal plasmatic flow (RPF) and glomerular filtrtaion rate (GFR). They also showed an increase in filtration fraction (FF) (p<0.05), diuresis and natriuresis. In the treatment for 28 days, there was an increase in BP (p<0.05), decrease in RPF (p<0.05), no changes in GFR and enhacement in FF (p<0.05). Both groups showed glomerular hypertrophy, increased desmin staining and proteinuria. The in vitro studies showed that leptin (100 and 250 ng/ml for 72 hours) induced mesangial cells apoptosis. In conclusion, the treatment with leptin for 7 and 28 days induced renal morphofunctional changes and they are mostly normalized by Losartan, demonstrating an interaction between leptin and systemic RAS, in this experimental model.
|
113 |
"Efeitos da sobrecarga ou restrição crônica de sal na dieta durante a gestação e amamentação em ratas Wistar e sua repercussão sobre a prole". / Renin-angiotensin system function and blood pressure in adult rats after perinatal salt overloadAlexandre Alves da Silva 19 April 2001 (has links)
Alguns estudos têm procurado avaliar os efeitos de variações no consumo de sal no período perinatal sobre o sistema cardiovascular da prole na idade adulta. No entanto, várias questões ainda estão em aberto e merecem estudos adicionais. Neste trabalho, o OBJETIVO foi estudar os efeitos da sobrecarga ou restrição crônica de sal na dieta de ratas Wistar, durante a gestação e amamentação, sobre o ganho de peso, a pressão arterial, a sensibilidade da pressão arterial ao sal (SENS), a atividade do sistema renina-angiotensina, o conteúdo renal de angiotensina II (AII) e a densidade glomerular da prole na idade adulta. Foram utilizadas fêmeas Wistar recém desmamadas divididas em 3 grupos: dieta hipo (HO - 0,15% NaCl - n=8), normo (NR - 1,27% NaCl - n=9) ou hipersódica (HR 7,94% NaCl - n=8). A quantidade de dieta oferecida as ratas foi ajustada de forma a manter o peso semelhante entre os grupos. A fecundação ocorreu na 12a semana de idade. Após o parto, apenas 8 recém-nascidos (4 machos e 4 fêmeas) permaneceram com suas mães. Após o desmame, todos os animais da prole receberam apenas a dieta NR. O peso materno foi medido diariamente até a fecundação e semanalmente até uma semana após o parto. O peso da prole foi medido no dia do parto e semanalmente após o desmame. A PA caudal materna foi medida desde uma semana antes da fecundação até uma semana após o parto (PAc-M) e na prole entre a 8a e a 12a semana de idade (PAc-P). Ao completar 12 semanas de idade, a prole foi submetida a um teste de sensibilidade da pressão arterial ao sal (1 semana em dieta HO seguido por 1 semana em dieta HR ou vice-versa). A atividade de renina plasmática (ARP) foi medida ao final de cada semana do teste. O conteúdo renal de AII foi avaliado por imunohistoquímica e a densidade glomerular através de um método histológico apropriado para a contagem dos glomérulos. Durante a gestação, a PAc-M foi maior no grupo HR (p<0,05) comparado aos grupos HO e NR. Na prole: 1) o ganho de peso foi menor (p<0,05) no grupo HR; 2) a PAc-P foi maior (p<0,05) no grupo HR, 3) a SENS foi menor (p<0,05) nas fêmeas do grupo HR, 4) uma semana de sobrecarga salina reduziu a ARP (p<0,05 vs. ARP após uma semana de restrição salina) nos grupos HO e NR, mas não no HR, 5) o conteúdo de AII renal foi maior no grupo HR (p<0,05) e 6) não foram observadas diferenças na densidade glomerular entre os grupos. Sobrecarga crônica de sal na dieta durante a gestação e amamentação, aumenta a pressão arterial materna e leva a um distúrbio na modulação do sistema renina-angiotensina sistêmico e renal da prole, o que pode explicar os maiores níveis pressóricos e a menor sensibilidade ao sal da prole do grupo HR na idade adulta e também acarreta um menor ganho de peso destes animais. / To study the influence of high salt intake during pregnancy and lactation on body weight, blood pressure, and the function of the renin-angiotensin system in adult rats. METHODS AND RESULTS: Female Wistar rats received a low (0.15 NaCl), normal (1.30), or high (8% diet) salt diet. Mating occurred on the 12th week of age. From weaning, the offspring received normal salt diet. Weekly tail-cuff blood pressure and body weight measurements were performed during pregnancy and in the offspring (body weight since weaning and tail-cuff blood pressure between the 8th and the 12th week of age). Salt sensitivity of the blood pressure was evaluated and plasma renin activity determinations were performed in the 12-week-old offspring. Immunohistochemistry for renal angiotensin II was performed in the adult offspring. Renal mass and the number of glomeruli were determined. Tail-cuff blood pressure was higher in salt overloaded dams than in normal and low salt ones. In the adult offspring from the high salt dams, lower body weight, higher tail-cuff blood pressure, lower salt sensitivity in females, and increased kidney angiotensin II were observed. Plasma renin activity did not change with changes in salt intake in the adult offspring submitted to high salt environment during the perinatal period. In the offspring, renal mass and the number of glomeruli were not influenced by the dams' salt intake. CONCLUSIONS: Salt overload during pregnancy and/or lactation has long-term effects on offspring's body weight and blood pressure. In addition, high salt diet during the perinatal period induced renin-angiotensin system functional disturbances in the offspring.
|
114 |
O sistema renina-angiotensina na doença periodontal induzida experimentalmente em ratos / The renin-angiotensin system in experimentally-induced periodontal disease in ratsMarta da Cunha Lima 18 August 2011 (has links)
A doença periodontal (DP) compreende um grupo de lesões que afetam os tecidos periodontais de proteção (gengivite) e suporte (periodontite), envolvendo a participação de células residentes, células estruturais e mediadores inflamatórios. Pesquisa recente do nosso laboratório mostrou a existência de um Sistema Renina-Angiotensina (SRA) local no tecido gengival de ratos e sugeriu que o SRA possa ter participação na DP. Portanto, o objetivo deste trabalho foi avaliar a se o SRA está envolvido na iniciação e na progressão da DP induzida experimentalmente em ratos. Para tanto, foi utilizado modelo de indução da DP por colocação de ligadura, por 7 e 14 dias, ao redor do primeiro molar inferior de ratos e tratamento destes animais com drogas que afetam o SRA [losartan (50 mg/Kg/dia), alisquireno (30 mg/Kg/dia) ou enalapril (10 mg/Kg/dia)]. Foram realizadas técnicas de análise da perda óssea alveolar, reação em cadeia da polimerase (PCR) quantitativa e imunoistoquímica. Após a coleta, os dados foram devidamente analisados por meio de gráficos e tabelas, sendo utilizada ANOVA a 2 e 3 critérios e adotado nível de significância de 5%. Em nível protéico, houve aumento significativo da maioria dos componentes do SRA (p<0,05) na DP. A renina apresentou aumento nos tratamentos com losartan, alisquireno e enalapril tanto nos animais sham (cirurgia fictícia de indução da DP) quanto nos animais com DP, aos 7 e 14 dias, e não apresentou marcação no grupo controle (água), demonstrando efeito dependente dos tratamentos farmacológicos. Na DP houve aumento dos componentes AT1 (aos 7 e 14 dias), AT2 (aos 7 dias) e enzima conversora da angiotensina (ECA; aos 7 e 14 dias) nos grupos tratados com losartan, alisquireno e enalapril. Também houve aumento de imunomarcação nos animais com DP para AT2 (aos 14 dias) e ECA (aos 14 dias) em animais do grupo controle. Em relação à expressão gênica, houve aumento da expressão de RNAm nos animais com DP para o receptor AT2 no grupo controle (aos 7 e 14 dias), e nos animais tratados com losartan ou enalapril (aos 7 dias). Houve aumento da expressão de RNAm para a ECA nos animais com DP tratados com losartan e enalapril (aos 7 dias), e controle (aos 14 dias). O tratamento por 14 dias com as drogas losartan ou alisquireno, mas não com enalapril, foi capaz de diminuir significativamente a perda óssea alveolar (p<0,05). Portanto, pode-se concluir que o SRA está envolvido na iniciação e na progressão da DP induzida experimentalmente em ratos. / Periodontal disease (PD) comprises a group of lesions that affect protection (gingivitis) and support periodontal tissues (periodontitis) involving the participation of resident and structural cells as well as inflammatory mediators. Recent research in our laboratory showed the existence of a local gingival renin-angiotensin system (RAS), and suggested that it might participate in PD. Therefore, the aim of this study was to evaluate whether the RAS is involved in the initiation and progression of the experimentally-induced PD in rats. For this purpose, a model of ligature placement, for 7 and 14 days, around the lower first molar in rats, and the treatment of such animals with drugs that affect the RAS [losartan (50 mg/Kg/day), aliskiren (30 mg/Kg/day) or enalapril (10 mg/Kg/day)] were employed. The following techniques were performed: alveolar bone loss analysis, quantitative real-time polymerase chain reaction and immunohistochemistry. Data were collected, organized in tables and graphs, and submitted to 2 and 3 way ANOVA with significance level established at 5%. In the protein level, there was a significant increase in the majority of the RAS components in PD. Immunolocalization for renin increased when animals were treated with losartan, aliskiren or enalapril, for 7 and 14 days, in both sham (fictitious surgery for PD induction) and PD animals, whereas the control group (water) had no staining, demonstrating a drug-related effect. In animals with PD treated with losartan, aliskiren or enalapril there was an increase in staining for AT1 (at 7 and 14 days), AT2 (at 7 days) and angiotensin-converting enzyme (ACE; at 7 and 14 days). There was also increased staining in PD animals for AT2 (at 14 days) and ACE (at 14 days) in the control group. As far as genic expression, there was an increase in mRNA expression for AT2 in control animals with PD (at 7 and 14 days), and in the animals treated with losartan or enalapril (at 7 days). There was an increase in mRNA for ACE in animals with PD treated with losartan or enalapril (at 7 days) as well as control rats (at 14 days). Treatment for 14 days with losartan or aliskiren, but not enalapril, significantly decreased alveolar bone loss (p<0.05). Therefore, one can conclude that the RAS is involved in the initiation and progression of the experimentally-induced PD in rats.
|
115 |
\"Caracterização funcional de vias formadoras de angiotensina II em carótidas de ratos\" / Role of elastase-2, an angiotensin converting enzyme, in carotid of rats.Christiane Becari 06 February 2004 (has links)
Uma atividade funcional para uma via alternativa de geração de angiotensina II, como a elastase-2 foi sugerida em estudos realizados anteriormente em nosso laboratório no leito arterial mesentérico isolado de rato. No presente estudo, caracterizamos com o uso de substratos e inibidores seletivos a presença de via alternativa de geração de Ang II, independente da ECA, em carótida de ratos. Determinamos ainda a expressão do RNAm da elastase-2 nesta preparação arterial. Em anéis isolados de carótida de ratos analisamos o efeito vasoconstritor dos peptídeos Ang II, Ang I, TDP, [Pro11-D-Ala12]-Ang I (um substrato resistente a ECA) na ausência e presença de inibidores de proteases. Ang II e seus precursores produziram efeito vasoconstritor dependente da concentração em carótidas de ratos, de forma sensível ao losartan (1 M). Na presença de captopril (10 M) a resposta vasoconstritora produzida pela Ang I foi inibida, mas a resposta contrátil induzida pelo TDP e [Pro11-D-Ala12]-Ang I não foi alterada. Na presença de quimostatina (100 M) o efeito produzido pelo TDP e [Pro11-D-Ala12]-Ang I foi abolido enquanto que a curva cumulativa de Ang I foi significativamente deslocada para a direita. Inibidor Ac-AAPL-CK (seletivo para elastase-2) aboliu completamente a resposta contrátil induzida pelo PDA e não alterou o efeito vasoconstritor da Ang II. Na presença de captopril e quimostatina a resposta vasoconstritora dos peptídeos Ang I, TDP e [Pro11-D-Ala12]-Ang I foram inibidas, enquanto a resposta contrátil da Ang II não foi alterada em artéria carótida. A presença de RNAm da elastase-2 na carótida, juntamente com os dados funcionais apresentados aqui sugerem a participação desta enzima na via alternativa de geração de Ang II em carótidas de ratos. Embora a formação de Ang II a partir Ang I seja descrita como essencialmente dependente da ECA, nossos resultados sugerem a existência de vias alternativas de geração de Ang II sensível a quimostatina e Ac-AAPL-CK em artéria carótida de ratos. Muito provavelmente a elastase-2 seja a enzima responsável pela geração de Ang II nessa preparação. / We have recently described a chymostatin-sensitive elastase-2 as the major angiotensin (Ang) II-forming enzyme in the perfusate of rat mesenteric arterial bed (MAB). In the present study we investigated the role of this enzyme in generating Ang II in the isolated rat carotid artery rings by analyzing the vasoconstrictor effect of Ang II, Ang I, tetradecapetide renin-substrate (TDP), [Pro11-D-Ala12]-Ang I (an ACE-resistant substrate) in the absence and presence of proteases inhibitors. Ang II and its precursors produced a dose-dependent vasoconstrictor effect in vascular preparation that was blocked by losartan (1 M). In carotid rings, captopril (10M) abolished the responses induced by Ang I but did not affect those induced by TDP and [Pro11-D-Ala12]-Ang I. In the presence of chymostatin (100 M) alone, the effects induced by [Pro11-D-Ala12]-Ang I and TDP were abolished while the concentration-response curve to Ang I was shifted to the right. Ac-AAPL-CK (selective elastase-2 inhibitor) inhibited the responses induced by [Pro11-D-Ala12]-Ang I but did not affect Ang II-induced effects. In the presence of captopril and chymostatin, the vasoconstrictor effects of Ang I, TDP, and PDA were completely blocked while those induced by Ang II were not affected in rat artery carotid. Although Ang II formation from Ang I is essentially dependent on ACE in carotid artery, our results suggest the existence of an alternative chymostatin-sensitive pathway in rat arteries, most probably involving elastase-2.
|
116 |
Effekt av ACE-hämmare på incidens av hjärt-kärlsjukdom och mortalitet hos diabetiker typ 2 samt av diabetes hos hypertonipatienter. / The effect of ACE inhibitors on cardiovascular diseases and mortality in type 2 diabetic and diabetic in hypertensive patients.SALEH, MASRA January 2013 (has links)
Background: Diabetes mellitus is a chronic disease that manifests as an increased level of glucose in the blood. According to the World Health Organization (WHO), 347 million people have diabetes worldwide. In year 2004, 3.4 million people died from the consequences of high blood glucose. In the Swedish population the prevalence of diabetes is estimated to 3-4 %, out of which 85-90% are Type 2. Among senior citizens a prevalence of diabetes is seen in Sweden up to 14 - 15%. Diabetes is increasing globally, particularly in developing countries, which is probably a consequence of the increased prevalence of overweight and obesity combined with low physical activity. Angiotensin converting enzyme (ACE) inhibitors are the first-line therapy in the treatment of high blood pressure among diabetics and patients suffering from congestive heart failure. The action of these inhibitors results in a decreased formation of angiotensin 2, an endogenous hormone peptide that raises the blood pressure by contracting the blood vessels. ACE inhibitors are also beneficial in the treatment of patients with renal insufficiency.Objective: The aim of this project was, with the help of published clinical trials and meta-analysis, to examine the effect of ACE inhibitors on cardiovascular diseases and mortality in type 2 diabetic and diabetic in hypertensive patients.Results: Appraisals of clinical trials within the frame of this project revealed thatACE inhibitor in patients with diabetes reduces:- Myocardial infarction (NNT = 37 during 4.5 years),- Development of stroke (NNT = 32 during 2.8 years),- Cardiovascular events (NNT = 29 during 4.5 years),- Total mortality (NNT = 20 during 2.8 years).- Left ventricular dysfunction (NNT = 6 during 3.4 years)- Complications that usually occur in association with diabetes such as nephropathy (NNT = 83 during 5 years).Conclusion: ACE inhibitors are considered well-established and safe drugs. Despite that, only 38% of the patients with diabetic in Sweden are prescribed ACE inhibitors or angiotensin II antagonists. Due to the high efficacy of ACE-inhibitors among patients with diabetes (i.e. treating 15 high-risk diabetic patients with ACE-inhibitors for a median of 4.5 years prevents one incidence of myocardial infarction, stroke, or cardiovascular mortality) measures ought to be taken in favour of a more widespread use of ACE-inhibitors among patients with diabetes. This will result not only in medical benefits, but also in reducing cost of caring for the elderly diabetics in the community. For most diabetic patients it is very cost effective to prescribe an ACE-inhibitor therapy.
|
117 |
Le système rénine-angiotensine (SRA) dans l'émergence hématopoïétique au cours de l'ontogenèse / The Renin-Angiotensin System (RAS) in hematopoietic emergence during ontogenyBiasch, Katia 11 July 2012 (has links)
Nous avons montré que l'enzyme de conversion de l'angiotensine (ACE) est un nouveau marqueur de la cellule souche hématopoïétique et identifie l’émergence de l'hématopoïèse dans tous les sites hématogènes de l’embryon humain. L'ACE fait partie du système rénine-angiotensine (SRA) dont la fonction principale est d'agir sur l'angiotensine I pour former l'angiotensine II (AngII), un puissant vasoconstricteur.De plus, nous montrons que les principaux composants du SRA (les récepteurs AT1 et AT2, l’angiotensinogène et la rénine) sont exprimés dans la même région de l'embryon qui exprime l'ACE, suggérant ainsi l’existence d’un SRA local dans l'embryon précoce. Des tests fonctionnels, conduits in vitro chez l'embryon de la souris, montrent que l’Ang II stimule dans la culture l'émergence des progéniteurs hématopoïétiques, effet qui peut être bloqué par un antagoniste spécifique de l’AT1. Ces observations suggèrent pour la première fois, le rôle direct du SRA dans l’émergence hématopoïétique au cours de l’ontogenèse. De plus, nous mettons en évidence l'existence d'un SRA local dans la moelle osseuse (MO) adulte et nous montrons que les principaux éléments de ce système sont surexprimés dans la MO de patients atteints de leucémie aiguë myéloïde, aussi bien dans les blastes que dans les cellules stromales. Ces observations suggèrent une contribution du SRA à la dérégulation de la niche observée dans les hémopathies.Ainsi, la présence d’un SRA local dans la niche hématopoïétique intra-embryonnaire et dans la MO chez l’adulte place ce système dans une position stratégique comme acteur important de l’émergence et de la régulation du système sanguin définitif. / We have shown that the angiotensin-converting enzyme (ACE) is a new marker of human hematopoietic stem cells and also identifies emerging hematopoiesis in all hemogenic sites inside the human embryo. ACE is a key component of renin-angiotensin system (RAS) as it catalyses the production of angiotensin II (Ang II) well known for its effect in the control of blood pressure, through AT1 and AT2 receptors.Furthermore, we observe the presence of the main elements of the RAS (AT1, AT2 receptors, angiotensinogen and renin) in the same region of the embryo expressing ACE, meaning that a local RAS exists in the embryo. Functional in vitro analyses, carried out in mouse model, show a stimulatory effect of AngII in the hematopoietic precursors emergence, an effect inhibited by a specific AT1 antagonist. These observations suggest for the first time a direct role of RAS in the emergence of hematopoiesis during ontogeny. In addition, our data indicate the presence of a local RAS inside the adult bone marrow (BM). This system is overexpressed in the BM of acute myeloid leukemia (AML) patients, both in hematopoietic cells and in stromal cells suggesting a RAS contribution to the bone marrow niche deregulation, always observed in these hemopathies.Therefore, the existence of a local RAS in the intraembryonic niche and in the adult bone marrow suggests that this system is an important actor in the emergence and regulation of the definitive blood system.
|
118 |
Characterization of [11C]Methyl-Losartan as a Novel Radiotracer for PET Imaging of the AT1 ReceptorAntoun, Rawad January 2011 (has links)
The Angiotensin II Type 1 (AT1) receptor is the main receptor responsible for the effects of the renin-angiotensin system, and its expression pattern is altered in several diseases. [11C]Methyl-Losartan has been developed based on the clinically used AT1 receptor antagonist Losartan. The aim of this work is to characterize the pharmacokinetics, repeatability and reliability of measurements, binding specificity and selectivity of [11C]Methyl-Losartan in rats using in vivo small animal positron emission tomography (PET) imaging, ex vivo biodistribution and in vitro autoradiography methods. Also, we aim to measure the presence of metabolites in the kidney and plasma using high-performance liquid chromatography. We have demonstrated in vivo that [11C]Methyl-Losartan is taken up in the AT1 receptor-rich kidneys and that it is displaceable by selective AT1 receptor antagonists. Using ex vivo biodistribution, we have confirmed these results and demonstrated that [11C]Methyl-Losartan binds selectively to the AT1 receptor over the AT2, Mas and β-adrenergic receptors. In vitro autoradiography results confirmed these renal binding selectivity studies. [11C]Methyl-Losartan was also shown to have one and two C-11 labeled metabolites in the plasma and kidneys, respectively. In conclusion, [11C]Methyl-Losartan is a promising agent for studying the AT1 receptor in rat models with normal and altered AT1 receptor expression using small animal PET imaging.
|
119 |
"Participação do sistema renina angiotensina na hipertrofia cardíaca induzida pelo treinamento resistido" / ROLE OF THE RENIN-ANGIOTENSIN SYSTEM IN RESISTANCE EXERCISE-INDUCED CARDIAC HYPERTROPHYValerio Garrone Barauna 07 March 2006 (has links)
Para avaliar a participação do Sistema Renina Angiotensina (SRA) sobre a Hipertrofia Cardíaca de ratos submetidos ao treinamento resistido foram usados 64 Ratos Wistar divididos em: Controle (CO), Treinado (TR), Controle ou Treinado tratados com Losartan (LOS; 20mg/Kg/d) e Controle ou Treinado tratados com NaCl (SAL; 1% água). Os grupos treinados realizaram quatro séries de 12 repetições, 5x/sem/8sem, com 65-75% de 1 Repetição Máxima (1RM). Hipertrofia cardíaca (HC), obtida pelo peso úmido do VE corrigida pelo Peso Corporal (PC) e pelo Ecocardiograma, foi observada no grupo TR com nenhum prejuízo da função ventricular. Tanto a atividade da ECA, sistêmica e local no coração, quanto a atividade da renina não foram alteradas pelo treinamento. Pelo Western blotting, não foi observada alteração na expressão protéica do peptídeo angiotensina II e do receptor de angiotensina II AT2 com o treinamento, mas observou-se aumento de 31,4% na expressão dos receptores de angiotensina II AT1 no grupo TR. A administração do antagonista do receptor AT1 (Losartan) preveniu a HC em resposta ao treinamento. O mesmo não foi observado com a administração do NaCl para inibir a atividade da Renina. Esses resultados sugerem que o receptor AT1 participa da HC induzida pelo treinamento resistido sem a necessidade de aumento na concentração da angiotensina II cardíaca. Um possível mecanismo seria a ativação direta dos receptores AT1 pelo estiramento mecânico dos cardiomiócitos. / Besides the well-known effects of Ang II in stimulating pathological pressure-overload cardiac hypertrophy, little information is available regarding the role of Renin-Angiotensin-System (RAS) in the exercise training-induced cardiac hypertrophy. 64 male Wistar rats were divided into 6 groups: Sedentary, Trained, Sedentary or Trained + Losartan (20mg/Kg/d, n=7) and Sedentary or Trained + Salt (NaCl 1%). The exercise protocol was: 4 x 12 bouts, 5x/week during eight weeks, with 65-75% of 1 Repetition Maximum (1RM). Using LV weight/body weight ratio and echocardiography (ECHO) we have observed cardiac hypertrophy in the Trained group without any impairment in ventricular function. Concerning RAS, neither ACE, analyzed by fluorometric assay (systemic and local in the heart), nor Renin, by RIA, activities were altered after resistance training. In addition, using Western blotting analysis, no change was observed in cardiac Ang II and AT2 receptor levels while the AT1 receptor expression was upregulated in Trained groups by 31,4%. Administration of the AT1 receptor antagonist (losartan) prevented left ventricle hypertrophy in response to the resistance training. The administration of salt, to inhibit the renin activity, did not prevent the cardiac hypertrophy. These results suggest that the AT1 receptor participates in resistance-training-induced cardiac hypertrophy without an increase in Ang II concentration in the heart. A possible mechanism is the direct activation of the AT1 receptor by mechanical stretching of cardiomyocytes.
|
120 |
Rat angiotensin-converting enzyme : tissue specific expression during pharmacological inhibitionBrice, Edmund Andrew William January 1995 (has links)
The renin-angiotensin system plays a central role in the maintenance of blood pressure. Angiotensin II, the main effector of this system, results from the action of angiotensin-converting enzyme (ACE) on angiotensin I. Angiotensin II, maintains vasomotor tone via its vasoconstrictor action, and also increases salt and water retention by stimulating the release of aldosterone. ACE inhibitors, such as captopril, enalapril and lisinopril, are highly effective in the treatment of hypertension and congestive cardiac failure. Previous studies have suggested that angiotensin converting enzyme (ACE) production may be enhanced during pharmacological inhibition of the enzyme. Little is known, however about the mechanism of this induction. After demonstrating increases in circulating ACE protein in cardiac failure patients receiving the ACE inhibitor captopril, a rat model was used to study this effect. A sensitive enzyme linked immunosorbent assay for rat ACE was developed and a partial cDNA for rat ACE cloned to enable examination of ACE mRNA and protein expression during enzyme inhibition with enalapril. Rat lung ACE mRNA increased by 156% (p<0.05) and ACE protein doubled within 3 hours of administering a single dose of enalapril. Testicular ACE mRNA also increased by 300% (p<0.05) within 2 hours and returned to pretreatment levels by 6 hours. The angiotensin II antagonist saralasin similarly caused a significant (p<0.0001) 800% enhancement of mRNA expression. Aldosterone pretreatment of rats prior to enalapril administration was found to abolish this mRNA induction. These findings indicate that increased ACE expression during inhibition results from reduced levels of angiotensin II with consequent reduced stimulation of the angiotensin 11 receptor and its effects, such as aldosterone release. This suggests that ACE levels are regulated by a negative feedback loop involving the distal components of the renin-angiotensin system, namely angiotensin II and aldosterone. In situ hybridisation and immunohistochemical techniques were employed to localise the site of this inductive response in rat tissue sections. It was found that lung macrophages were markedly induced to produce ACE, as was ACE in seminiferous tubules. ACE induction was also noted in the expected sites of renal tubular epithelium and glomerular tissue. Interestingly, ACE expression was also enhanced in cardiac valves. In these studies it has been conclusively demonstrated that new ACE expression is induced by enzyme inhibitor therapy. A variety of techniques have been developed that will allow futher study of ACE in rat tissues.
|
Page generated in 0.0759 seconds